Global
esophageal cancer therapeutics market is expected to witness significant growth
with an increasing awareness regarding cancer treatment and technological
advancements. Also, high demand for safe and effective medications and rising
prevalence of cancer are driving the growth of the global market. The
regulatory bodies such as USFDA, EMA are supporting the growth of the global
market by providing funding, designations and grants for speeding up the drug
development process.
Esophageal
cancer involves formation of malignant cells in the tissues of the esophagus.
Esophagus is a muscular tube that enable food and liquids to move from the
throat to the stomach. The main types of esophageal cancer are adenocarcinoma
and squamous cell carcinoma. Adenocarcinoma forms in cells that produce and
release mucus and other fluids. Squamous cell carcinoma forms in flat cells
lining the esophagus. Esophageal squamous cell carcinoma includes heavy alcohol
consumption and smoking as major risk factors, with gastroesophageal reflux
disease and Barrett esophagus further contributing as the risk factors of
esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms;
therefore, an advanced stage diagnosis is difficult.
Request to Get the
Sample Pages at:
Some of the
major drivers for the global esophageal cancer therapeutics market include
combination therapies, treatment advancements, increasing number of regulatory
approvals for esophageal cancer and a rise in the number of cancer treatment
centers. Moreover, the launch of new drug therapies for esophageal cancer is
expected to contribute as a key market driver in the near future. Also with a
dense pipeline, many new drug candidates are expected to enter the global
esophageal cancer therapeutics market. Safety concerns and efficacy of the
treatment are the major factors that can hinder the market growth over the
forecast period. Other factors hampering the market growth include low
availability of drugs commercially and high cost of therapy for the treatment
of esophageal cancer.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=esophageal-cancer-therapeutics-market
Certain
chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine,
Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine,
Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are well
established as a conventional method. Immunotherapy, combination therapy,
monoclonal antibodies and steroids have also been showing good results for the
treatment of esophageal cancer.
Some of the
key players operating in the global esophageal
cancer therapeutics market include Genentech, Inc.,
Sanofi-Aventis, Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., Merck
& Co., Inc., Johnson & Johnson Pharmaceutical Research &
Development, LLC, Gilead Sciences, and Bristol-Myers Squibb, among others.
